Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Jun 21.
Published in final edited form as: Expert Opin Drug Metab Toxicol. 2019 Jun 11;15(7):523–525. doi: 10.1080/17425255.2019.1628947

Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women

Ahizechukwu C Eke a,b, Mark Mirochnick c
PMCID: PMC9210948  NIHMSID: NIHMS1814974  PMID: 31185758

1. Introduction

Ritonavir and cobicistat are commonly used as pharmacokinetic enhancers to boost plasma concentrations of antiretrovirals used to treat HIV infection, including the protease inhibitors atazanavir, darunavir, and lopinavir, the integrase inhibitor elvitegravir, and the nucleotide reverse transcriptase inhibitor tenofovir alafenamide. Ritonavir and cobicistat inhibit metabolism and/or transport of the coadministered antiretroviral, increase its plasma concentration and prolong half-life, allowing more convenient and better tolerated dosing regimens. The physiologic changes associated with pregnancy can have a major impact on drug disposition and may limit the effectiveness of ritonavir and cobicistat when used in pregnant women living with HIV.

2. Ritonavir

Ritonavir was initially approved as a protease inhibitor in 1996 at doses of 600 mg twice daily, but its use was limited by poor tolerability, low potency, high pill burden, and frequent drug interactions. Use of full-dose ritonavir was often accompanied by adverse events including gastrointestinal intolerance, lipid elevations, and oral paresthesia [1]. Ritonavir drug interactions are due to its potent inhibition of metabolizing enzymes and transporters, including cytochrome p450 3A4 (CYP3A4), the intestinal transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), the hepatic organic anion transporting polypeptides (OATPs), and the multiantimicrobial extrusion protein 1 (MATE1) [2]. Ritonavir also activates the pregnane X receptor (PXR), inducing the activity of CYP1A2, CYP2B6, CYP2C9, and CYP2C19 and glucuronidation enzymes [2].

Ritonavir is now used almost exclusively at doses of 100–200 mg per day as a pharmacoenhancer for CYP3A4-metabolized drugs [1]. Ritonavir-boosted protease inhibitors are recommended as part of alternative antiretroviral regimens used to treat adults living with HIV [3]. The pharmacokinetics of the protease inhibitors atazanavir, darunavir, and lopinavir with ritonavir boosting have been studied in pregnant women [4]. Drug exposures for each of these boosted protease inhibitors are significantly reduced during pregnancy. Ritonavir area under the concentration -time curve (AUC) is reduced by 30–50% during pregnancy compared to postpartum, suggesting that inadequate inhibition of hepatic metabolism plays a large role in the reduction in drug exposure of these boosted protease inhibitors during pregnancy. Increasing the size of atazanavir or lopinavir doses during pregnancy results in plasma exposures nearly equivalent to those in nonpregnant adults, while increasing the darunavir dose does not improve plasma darunavir concentrations [4,5]. Protease inhibitors are highly protein bound, and decreased protein binding during pregnancy will result in a higher concentration of the pharmacologically active free (unbound) drug concentration at a given total (bound plus unbound) concentration, which may limit the therapeutic impact of reductions in total drug exposure during pregnancy [6]. Use of increased doses of ritonavir during pregnancy has never been studied out of concern that larger ritonavir doses would not be well tolerated by pregnant women. Placental passage of ritonavir is low, with a median ratio of cord blood to maternal delivery plasma ritonavir concentrations of 0.18 [7].

Current recommendations for protease inhibitor dosing during pregnancy include use of an increased dose of atazanavir (400 mg with ritonavir 100 mg once daily), consideration of use of an increased twice-daily lopinavir/ritonavir dose (from 400 mg/100 mg to 600 mg/150 mg), and avoidance of the use of lopinavir/ritonavir once daily. Since darunavir exposure was decreased more with once-daily dosing than twice-daily dosing during pregnancy and increasing the dose of darunavir during pregnancy to 800 mg twice daily did not increase darunavir plasma concentrations, standard twice-daily darunavir/ritonavir dosing is recommended during pregnancy (600 mg/100 mg twice daily), while once-daily dosing is not recommended [4].

3. Cobicistat

Cobicistat, initially approved in 2012, was developed as an alternative pharmacoenhancer with more favorable physiochemical properties than ritonavir. Cobicistat has no direct antiviral effects but is as strong an inhibitor of CYP3A4 and drug transporter as ritonavir [2]. Cobicistat is a weak in vitro activator of PXR, so is not likely to be an inducer of drug-metabolizing enzymes [2]. While ritonavir solubility is poor, limiting its ability to be coformulated with other antiretrovirals into more convenient fixed-dose combination products, cobicistat is readily coformulated with other antiretrovirals. Although cobicistat is available in a single drug formulation, it is most commonly used as part of fixed-dose combination products with other antiretrovirals, including the protease inhibitors atazanavir and darunavir, the integrase inhibitor elvitegravir, and the nucleotide reverse transcriptase inhibitor tenofovir alafenamide. Use of cobicistat-boosted combination formulations is recommended as alternative regimens for the treatment of adults living with HIV [3].

Experience with cobicistat in pregnant women is more limited than with ritonavir, but there are several reports of antiretroviral pharmacokinetics with use of cobicistat during pregnancy. Plasma cobicistat exposures are reduced by 44–54% during the second and third trimesters compared to postpartum [8]. When cobicistat is detectable in both cord blood and maternal blood at delivery, the median ratio of the cobicistat concentration in cord blood to that of maternal plasma is 0.09 [8]. Plasma concentrations of the targets of cobicistat boosting, including darunavir, elvitegravir, and atazanavir, are low with the use of cobicistat-boosted regimens in pregnancy [811]. When third-trimester pharmacokinetic parameters were compared to postpartum in women receiving elvitegravir/cobicistat, elvitegravir AUC was reduced by 44% and cobicistat AUC by 59% during the third trimester, and cobicistat AUC was negatively associated with elvitegravir apparent oral clearance [8]. Darunavir AUC is reduced by around 50% during the third trimester compared to postpartum [10,11]. Similar preliminary results have been presented on atazanavir exposure with the use of atazanavir/cobicistat during pregnancy [9]. As a result of these data, the product labels for cobicistat-containing formulations were changed in 2018 to state that these products are not recommended for initiation during pregnancy, and an alternative regimen is recommended for those who become pregnant during therapy with these products [12].

Cobicistat is also used to boost the nucleotide reverse transcriptase inhibitor tenofovir alafenamide. Tenofovir alafenamide is not a substrate for CYP3A4 metabolism, and cobicistat increases tenofovir alafenamide plasma concentrations due to its inhibition of the intestinal efflux transporters P-gp and BCRP and not by inhibition of CYP3A4 activity. Cobicistat is an effective booster of tenofovir alafenamide during pregnancy, in contrast to the experience with cobicistat and CYP3A4 substrates in pregnancy. Tenofovir alafenamide AUC is equivalent when dosed as 25 mg unboosted and 10 mg with cobicistat during pregnancy [13]. The difference in the ability of cobicistat to effectively boost tenofovir alafenamide and not CYP3A4 substrates during pregnancy suggests that while intestinal cobicistat concentrations during pregnancy are adequate to inhibit gut transporters, the bioavailability of cobicistat is too low during pregnancy to achieve plasma concentrations than can reach the liver and effectively inhibit hepatic CYP3A4 metabolism.

4. Expert opinion

Although ritonavir is not as effective a booster of CYP3A4-metabolized drugs during pregnancy as in nonpregnant adults, strategies such as increasing substrate doses and avoiding once-daily dosing schedules have been devised to overcome these limitations and allow ritonavir-boosted protease inhibitors to be used effectively during pregnancy. In contrast, cobicistat boosting of the CYP3A4 substrates elvitegravir, darunavir, and atazanavir during pregnancy is so poor that the product labels for the cobicistat-containing fixed-dose combination formulations of these drugs have been changed to state that the use of these products in pregnant women is not recommended [12]. Cobicistat is an effective booster of tenofovir alafenamide during pregnancy, acting via inhibition of gut transporters rather than hepatic CYP3A4 metabolism.

Unfortunately, because pregnant women are excluded from most premarketing clinical trials that lead to drug licensure, cobicistat-containing products were commercially available and widely used in pregnant women living with HIV for 6 years before post-marketing studies in pregnant women revealed their deficiencies when used during pregnancy. If drugs are to be used safely and effectively in pregnant women, then pregnant women should be included in clinical trials prior to licensing, so that when drugs are approved for use it is known whether and how they can be used during pregnancy [14,15]. New approaches to the design and conduct of pharmacokinetic studies, including use of physiologic-based pharmacokinetic modeling and simulations, may prove useful in accelerating and increasing the safety of dose-finding studies in pregnant women [16].

Declaration of interest

M Mirochnick has received research grant support from Merck, ViiV Healthcare and Gilead Sciences and has acted as consultant for ReViral. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Footnotes

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

  • 1.Renjifo B, van Wyk J, Salem AH, et al. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015. Jan-Mar;17(1):37–46. [PubMed] [Google Scholar]
  • 2.Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016. Jul;71(7):1755–1758. [DOI] [PubMed] [Google Scholar]
  • 3.HHS Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. [cited 2019 Apr 3]. Available from https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0
  • 4.Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [cited 2019 Apr 3]. Available from: https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0
  • 5.Stek A, Best BM, Capparelli E, et al. Pharmacokinetics of increased dose darunavir during late pregnancy and postpartum. 23rd Conference on Retroviruses and Opportunistic Infections; 2016. Feb 22-25; Boston, MA. [Google Scholar]
  • 6.Metsu D, Toutain PL, Chatelut E, et al. Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle? J Antimicrob Chemother. 2017. Sep 1;72(9):2407–2409. [DOI] [PubMed] [Google Scholar]
  • 7.Stek A, Best BM, Wang J, et al. Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women. J Acquir Immune Defic Syndr. 2015. Sep 1;70(1):33–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018. Nov 13;32(17):2507–2516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Momper JD, Stek A, Wang J, et al. , IMPAACT P1026s Protocol Team. Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. Noordwijk, the Netherlands. May 14-16, 2019. [Google Scholar]
  • 10.Crauwels HM, Osiyemi O, Zorrilla C, et al. Pharmacokinetics of total and unbound darunavir in HIV-1–infected pregnant women receiving a darunavir/cobicistat-based regimen. 8th International Workshop on HIV & Women; Mar 2-3, 2018; Boston, Massachusetts. [Google Scholar]
  • 11.Momper JD, Best BM, Wang J, et al. , IMPAACT P1026s Protocol Team. Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum. 22nd International AIDS Conference (AIDS 2018). Amsterdam, the Netherlands, Jul 23-27, 2018. [Google Scholar]
  • 12.Boyd SD, Sampson MR, Viswanathan P, et al. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint. AIDS. 2019. May 1;33(6):1089–1093. [DOI] [PubMed] [Google Scholar]
  • 13.Momper JD, Best BM, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. 22nd International AIDS Conference (AIDS 2018); 2018. Jul 23-27; Amsterdam, the Netherlands. [Google Scholar]
  • 14.Sheffield JS, Siegel D, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014. Dec 15;59(Suppl 7):S437–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Eke AC, Dooley KE, Sheffield JS. Pharmacologic research in pregnant women – time to get it right. N Engl J Med. 2019. Apr 4;380(14):1293–1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. CPT Pharmacometrics Syst Pharmacol. 2018. Feb;7(2):103–110. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES